

**केन्द्रीय मुहर विभाग -2**

संदर्भ -: के मू वी-2/16 : 14709

30 12 2022

**विषय: IS 14709 : 1999 के amendment no. 2 के अनुपालन के दिशा निर्देश**

यह उपरोक्त विषय के संदर्भ में है।

सक्षम अधिकारी द्वारा अनुमोदित दिशा निर्देश अनुपालन हेतु संलग्न है ।

सभी क्षेत्रीय/शाखा कार्यालयों से अनुरोध है की दिशा निर्देशों का तत्काल प्रभाव से अनुपालन सुनिश्चित करें।

(ज्ञान प्रकाश)

वैज्ञानिक- सी

**प्रमुख (के मू वी 2)**

सभी क्षेत्रीय/शाखा कार्यालय/प्रयोगशालाओं/PCD/LRMD

**CENTRAL MARKS DEPARTMENT-2**

Our Ref: CMD-2/16 : 14709

30 12 2022

**Subject : Guidelines for implementation of amendment no. 2 to IS 14709 : 1999**

This has reference to the subject mentioned above.

The Competent Authority has approved the enclosed Guidelines for implementation.

All ROs/BOs are requested to ensure the implementation of the above Guidelines with immediate effect.

(Gyan Prakash)  
Scientist-C

Head (CMD-2)

All ROs/BOs/Labs/PCD/LRMD

**CENTRAL MARKS DEPARTMENT-2**

**Our Ref: CMD-2/16 : 14709**

**30-12-2022**

**Subject: Guidelines for implementation of Amendment No. 2 to IS 14709 : 1999 n-Butyl Acrylate - Specification**

1. Amendment No. 2 to IS 14709 : 1999 has been published. The amendment shall be implemented with immediate effect.
2. All BOs shall inform the Applicants and Licensees under their jurisdiction about implementation of the above amendment within a week of issuance of these guidelines.
3. The significant changes in the standard through this amendment as listed in the Table are given for the purpose of general guidance.

Clause	Change
Page 1, Table 1, S No (v), col (4)	Option of using Annex A or Annex C has been given for testing the requirement of inhibitors (Earlier only Annex C was specified).  A note has also been added below Table 1, specifying that Annex A shall be the referee method for determination of inhibitors.

4. The existing Product Manual has been revised to incorporate the amendment and it is being circulated separately through BIS website, as Product Manual Doc : PM/ 14709/ 2 December 2022.
5. There is no change in the requirements of the standard through this amendment and only alternate Option of using Annex A or Annex C has been given for testing the requirement of inhibitors (Earlier only Annex C was specified).
6. In view of above, no evidence of conformity needs to be obtained from applicants/licensees. However, All BOs shall inform the Applicants and Licensees under their jurisdiction about implementation of the amendment within a week of issuance of these guidelines

**(Gyan Prakash)**  
**Sc-C, CMD-2**

**Head (CMD II)**

**DDG (Certification)**